Please login to the form below

Not currently logged in
Email:
Password:

Hichens Harrison completes USD 5.9m share placing for Mena

Hichens Harrison has revealed that its Middle-eastern investment vehicle, Mena Healthcare, is now valued at USD 7m, following a placing of 5.9m shares at USD 1.00 each.

Hichens Harrison has revealed that its Middle-eastern investment vehicle, Mena Healthcare, is now valued at USD 7m, following a placing of 5.9m shares at USD 1.00 each.

The stockbroking services company said the investment vehicle is focused on the Middle East and North Africa region, saying it expected healthcare expenditure to rise sharply over the coming years.

The AIM-listed company said it expects a second round of fundraising of up to a further USD 5.9m at USD 1.00 a share, to conclude in Q3 2007.

Hichens Harrison  holds 31.5 per cent or about USD 2.2m shares in Mena Healthcare.

Hitchens Harrison announced on 10 August that it had completed the acquisition of a 70 per cent controlling stake in an established operating business in Dubai, called Med Serve.

The company screens immigrant workers and expatriate applicants for United Arab Emirates (UAE) residency visas for certain medical conditions. Terms of the transaction were undisclosed.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics